Bariatric Surgery, Hypertension
Conditions
Keywords
Cardiac Function, Echocardiography
Brief summary
The purpose of this study is to investigate the effect of bariatric surgery on cardiac function assessed by echocardiography in patients with hypertension.
Detailed description
Obesity is the most common chronic metabolic disease worldwide, causing the increasing burden of cardiovascular risk factors such as hypertension, and affecting cardiac structure and function in the long term. Nowadays, bariatric surgery is regarded as the most effective approach for weight loss, and the only approach for reducing obesity-related cardiovascular events. However, the effect of different bariatric surgeries such as laparoscopic sleeve gastrectomy (LSG) or Roux-en-Y gastric bypass (RYGB) on cardiac function in patients with hypertension is still unclear. Therefore, the aim of this study was to evaluate the benefit of different bariatric surgeries on cardiac structure and function echocardiography in patients with hypertension.
Interventions
PROCEDURELSG
Laparoscopic sleeve gastrectomy (LSG) together with medical treatment aiming the control of cardiovascular risks including hypertension, diabetes mellitus or dyslipidemia.
PROCEDURERYGB
Roux-en-Y gastric bypass (LRYGB) together with medical treatment aiming the control of cardiovascular risks including hypertension, diabetes mellitus or dyslipidemia.
Sponsors
Beijing Friendship Hospital
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
17 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* 18-70 years old * BMI\>24kg/m2 * Bariatric surgery patients of Beijing Friendship Hospital * History of hypertension and treated with ≥2 antihypertensive drugs for more than 4 weeks * No major barriers to provide written consent
Exclusion criteria
* Secondary hypertension, except because of sleep apnea * cardiovascular disease (myocardial infarction, heart failure, stroke or coronary revascularization) within 6 months * Severe concomitant diseases (autoimmune disease, malignancy, late stage of liver diseases, respiratory diseases and digestive diseases) * Unable to understand or comply with the study procedures
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Changes on left ventricular ejection fraction (LVEF) | 12 months | Changes on LVEF in % assessed with the use of transthoracic echocardiography (TTE). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Changes on left ventricular ejection fraction (LVEF) | 24 months | Changes on LVEF in % assessed with the use of TTE. |
| Changes on left ventricular end-diastolic diameter (LVEDD) | 12 months | Changes on LVEDD in mm assessed with the use of TTE. |
| Major adverse cardiac events | 12 months | including all-cause mortality, cardiac death, acute myocardial infarction, stroke, heart failure, ventricular tachycardia or ventricular fibrillation requiring shock delivery. |
| Changes on number of antihypertensive drugs | 12 months | Changes on of the total number of antihypertensive medications while maintaining office systolic and diastolic blood pressure \<140 mm Hg and 90 mm Hg, respectively. |
| Changes on blood pressure | 12 months | Changes on systolic and blood pressure assessed with the use of 24-hour ABPM. |
Countries
China
Contacts
Primary ContactRongchong Huang, M.D.
Outcome results
None listed